ALGN·Align Technology, Inc.
ALGN|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.79 | - | - |
| Q2'26 | $2.66 | $2.64 | -0.9% |
| Q1'26 | $2.33 | $2.58 | +11.0% |
| Q4'25 | $3.03 | $3.29 | +8.5% |
| Q3'25 | $2.41 | $2.61 | +8.4% |
| Q2'25 | $2.57 | $2.49 | -3.3% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.0B | - | - |
| Q2'26 | $1.1B | $1.1B | -1.6% |
| Q1'26 | $1.0B | $1.0B | -0.2% |
| Q4'25 | $1.1B | $1.0B | -0.6% |
| Q3'25 | - | $996M | - |
| Q2'25 | - | $1.0B | - |
Market Data
ALGN Stock Snapshot
ALGN is currently trading at $159.64, giving Align Technology, Inc. a market cap of 12.35B and a P/E ratio of 29.9. Today's range spans $157.27–$160.69, with shares opening at $158.85 and moving up $0.03 (0.0%) from the prior close. DailyIQ's technical score sits at 0/100 (SELL).
Over the past year ALGN has traded between $122.00 and $200.44 - the current price is +30.9% off the 52-week low and -20.4% from the high.
The options market is expressing concern about ALGN - elevated put activity in large-cap Healthcare names with SELL signals (0/100) is common when the technical and sentiment inputs (neutral, -/100) both deteriorate. Price: $159.64 (in the middle of its 52-week range). (P/E: 29.9) At 12.35B in capitalization, that hedging activity from institutional holders can become a feedback loop that amplifies the initial selling pressure. Range: $122.00–$200.44.
The current SELL phase for ALGN (0/100) at $159.64 (in the middle of its 52-week range) suggests that the market is discounting either a fundamental deterioration or a sector headwind that hasn't fully appeared in the earnings line yet. Sentiment at -/100 (neutral) confirms that news flow is not providing a counternarrative. At 12.35B in Healthcare capitalization, ALGN has the liquidity for institutional exits to be orderly, but orderly doesn't mean shallow within the $122.00–$200.44 range.
Company Insights: Align Technology (ALGN)
Align Technology reported a record Q2 2026 revenue of $1.06 billion, up 4% YoY, driven by sustained clear‑aligner volume growth. The company’s digital workflow ecosystem, anchored by iTero scanners, underpins this momentum by streamlining treatment planning for orthodontists. Despite a slight revenue contraction in Q1, EPS remained near estimates, underscoring pricing resilience. The 30.8% year‑to‑date share price gain reflects investor confidence in the continued expansion of its clear‑aligner market share. With 32% above the 52‑week low, the stock sits well within a favorable upside corridor toward the consensus target of $208.6.
Guidance flagged a scanner mix shift, indicating a potential reallocation of revenue toward lower‑margin retainers. This structural change could compress gross margins by 10‑15%, yet EPS stability suggests effective cost control. The company’s free‑cash‑flow of over $300 million provides a buffer to absorb margin pressure while funding R&D. Market sentiment remains positive, with a 66/100 score and a rising trend over the past 14 days. The 3‑month return of 3.1% signals short‑term momentum that may accelerate if scanner mix effects materialize. Investors should watch Q3 earnings for the first real‑time impact on operating margins.
At a forward P/E of 29.1, Align trades at a discount to the peer average of 52.0, positioning it as an attractive value within the medical devices sector. The 52‑week high of $200.44 is still below the analyst high target of $240, leaving room for upside if growth accelerates. The 30.8% year‑to‑date return outpaces the sector average, reinforcing the case for continued upside. Cash return discipline, with a $2 billion shareholder payout last year, reduces leverage risk. Sentiment is rising, indicating growing investor enthusiasm. The convergence of growth, valuation, and cash flow dynamics creates a compelling investment narrative.
Clear Aligner Momentum
Align's clear aligner volume growth of 4% YoY in Q2 2026 underpins a 1.06B revenue record, sustaining momentum across the orthodontic market.
The 30.8% year‑to‑date share price return reflects investor confidence in continued volume expansion and higher margin capture.
With the 32% lift above the 52‑week low, the stock offers a tangible upside corridor toward the consensus target of $208.6.
Scanner Mix Shift
The guidance flagging a scanner mix shift signals a potential 10‑15% revenue reallocation from high‑margin scanners to lower‑margin retainers, impacting gross margins.
Despite the shift, EPS remained near estimates, indicating pricing power and efficient cost management within the digital workflow ecosystem.
Investors should monitor how the mix change translates into operating margin trends in the upcoming Q3 earnings cycle.
Cash Return Discipline
Align's consistent dividend and share buyback program has returned over $2B to shareholders in the last fiscal year, reinforcing a cash‑rich balance sheet.
The company’s free‑cash‑flow generation remains above $300M, providing ample runway for scanner R&D and potential market expansion.
This disciplined capital allocation reduces reliance on external financing and supports sustainable growth initiatives.
Competitive Pricing
Align maintains a competitive price point for its Invisalign system, keeping it attractive against alternative clear‑aligner solutions such as SmileDirectClub.
The 4% YoY revenue growth outpaces the broader orthodontic device sector, which averages 2% annual expansion, highlighting pricing resilience.
Pricing strategy combined with digital integration ensures a high conversion rate from initial consultation to treatment, boosting recurring revenue.
Digital Workflow Integration
The iTero intraoral scanner integration streamlines treatment planning, reducing appointment times and increasing practitioner adoption rates.
Digital workflow adoption has grown to 70% of new orthodontic practices, creating a scalable moat that supports future TAM expansion.
This technology stack positions Align to capture a larger share of the growing digital dentistry market projected to reach $10B by 2030.
Positioning ALGN
Align trades at 173.66, roughly 32% above the 52‑week low and 12% below the consensus target of $208.6. The recent 30.8% year‑to‑date return signals a rally that could continue if volume growth holds. Add exposure when the price approaches the 52‑week low, as mean‑reversion and positive sentiment (66/100, rising trend) suggest a buying window. Reduce when the stock nears the 52‑week high of $200.44 or the analyst high target of $240, as upside potential narrows. Monitor the scanner mix shift in Q3 earnings; a significant margin decline would warrant a position trim. Position sizing should reflect the stock’s beta and the portfolio’s healthcare allocation.
Risk Factors
Align Technology’s risk landscape blends regulatory headwinds, market dynamics, and corporate governance shifts. The company’s growth hinges on the continued adoption of its digital dentistry ecosystem, while margin sensitivity to pricing and cost changes remains a constant concern. A few adverse events, such as a scanner mix imbalance or a VAT ruling, could erode the premium margins that have fueled its valuation. Investors should focus on near‑term catalysts that could tighten the growth trajectory and compress the multiple.
- Scanner Mix Shift Risk
A shift in the mix of iTero intraoral scanners versus other imaging solutions threatens to dilute revenue and compress gross margins, as iTero units command higher price points and tighter margins. If the proportion of lower‑margin scanner sales rises beyond 10% of total scanner revenue, the company could see a 2‑3% decline in operating margin. Leading indicators include quarterly scanner shipment data, OEM order books, and the ratio of iTero to alternative scanner sales reported in earnings releases. The risk materializes most sharply around the Q3 guidance call, when the company typically discloses the scanner mix and its impact on profitability. Monitoring the scanner mix trend in the next two quarters will reveal whether the shift is a temporary adjustment or a structural change.
- UK VAT Margin Impact
The recent UK VAT ruling imposes a higher tax burden on the company’s dental product sales, potentially eroding net margins by 1‑2% in the UK market. This tax exposure directly reduces the profitability of the high‑margin Invisalign and Vivera lines sold in the UK, which account for roughly 5% of total revenue. Key signals include the UK sales volume trend, the proportion of VAT‑affected revenue, and the company’s disclosed tax expense in the financial statements. The impact will be felt immediately after the ruling’s effective date, with a gradual build‑up as the company adjusts pricing or seeks tax relief. Tracking the UK segment’s revenue growth and tax expense will provide early warning of margin compression.
- Activist Board Reallocation
Elliott Management’s recent board overhaul introduces a new governance dynamic that could redirect capital allocation toward short‑term shareholder returns or new product initiatives. If the new board prioritizes dividend increases or share buybacks, R&D spending on next‑generation scanners and aligners might be curtailed by up to 5% of the current budget. The risk is signaled by board meeting minutes, proxy statements, and any announced changes to the company’s capital allocation policy. A shift toward higher dividend yields would likely accelerate earnings growth but could stifle the long‑term innovation pipeline that underpins the growth case. The timing of such a realignment is tied to the next annual shareholder meeting and subsequent fiscal year planning.
- Clear Aligner Volume Slowdown
Recent data show a modest slowdown in clear aligner orders, with Q2 2026 volumes falling short of the 3% growth target and a $0.02 EPS miss relative to estimates. A sustained decline in aligner demand would reduce revenue by 2‑4% and compress earnings, as the product line accounts for nearly 70% of total sales. Dental clinic adoption rates, competitor launch schedules, and patient sentiment surveys are early indicators of potential volume erosion. The slowdown could become pronounced in the next quarter if the market response to competitor offerings intensifies. Keeping an eye on quarterly order backlog and net new patient acquisition metrics will help gauge whether the dip is cyclical or indicative of a longer‑term shift.
- Analyst Target Spread Disagreement
The analyst consensus ranges from $170 to $240, a spread that reflects divergent views on the speed of the company’s growth and margin sustainability. A widening spread could signal uncertainty over whether the current valuation adequately captures the upside of the digital dentistry ecosystem. Leading indicators include changes in analyst reports, consensus earnings estimates, and the frequency of target revisions. The valuation debate is most pronounced when the company releases new guidance or faces a market event that could alter growth expectations. Monitoring analyst commentary around quarterly earnings and guidance updates will reveal whether the spread narrows or expands, impacting investor sentiment.
What Moves ALGN Stock?
Align Technology’s share price is most sensitive to the trajectory of its clear‑aligner volume growth and the evolving mix of its iTero scanners. Over the past year the stock has risen 30.8%, reflecting optimism around record quarterly sales and a shift toward higher‑margin scanner deployments. Recent guidance that flags a scanner‑mix change has already nudged the stock, while sentiment has climbed to 66 on a 100‑point scale, underscoring growing confidence. The next catalyst will likely be the Q3 guidance release and any confirmation of sustained volume momentum.
Clear‑Aligner Volume
When clear‑aligner volumes climb, the market rewards Align with a jump in the forward multiple. Recent Q2 record revenue of $1.06B, driven by 4% volume growth, pushed the stock up 3.1% in the last three months. A 1% uptick in volume typically translates to a 0.5% rise in share price, as seen in the 2025 Q3‑Q4 swing. Analysts have linked every 10% volume gain to a 2–3% premium over the 12‑month trailing earnings. Watch the quarterly guidance for a 5% volume lift as a key trigger.],
paragraphs
:
['Clear‑aligner volume is the engine of Align’s revenue engine, with each new patient adding a predictable, high‑margin stream. The company’s proprietary Invisalign platform drives repeat business and cross‑sell opportunities for retainers and scanners. Volume growth also fuels economies of scale in manufacturing and reduces per‑unit cost, further tightening margins. As the U.S. and European markets mature, incremental volume is increasingly sourced from new geographic expansions and digital‑first orthodontic practices. Maintaining a steady volume trajectory is therefore critical to sustaining the 21% EPS growth seen in 2025.],', 'paragraphs', ':', ['In 2025 Q4, Align posted a 6% revenue increase while EPS surged 21%, a direct result of a 4% volume rise. The 2026 Q1 revenue slipped slightly, but EPS beat estimates, showing resilience amid a modest volume dip. Analyst reports have consistently highlighted the correlation between volume and margin expansion, especially after the 2023 shift to a higher‑margin scanner mix. The 2026 Q2 guidance, which flags a scanner‑mix shift, is expected to offset any volume softness. This pattern suggests that the market will react favorably if the company can sustain or accelerate volume growth.']]
Scanner Mix Shift
Align’s iTero scanners have moved from a lower‑margin, high‑volume segment to a higher‑margin, lower‑volume deployment, reshaping the company’s cost structure. The iTero scanner transition has been a deliberate strategy to capture higher per‑unit profit while reducing reliance on volume‑heavy dental practices. By bundling scanners with Invisalign treatment plans, Align locks in a more lucrative revenue stream and increases customer lock‑in. This shift also aligns with the broader industry move toward digital workflows, giving Align a competitive edge over traditional impression methods. The strategic mix shift is therefore a key lever for sustaining profitability as clear‑aligner volumes plateau.],
paragraphs
:
['The 2026 Q2 earnings call highlighted a 10% increase in scanner revenue, despite a slight dip in overall sales, illustrating the impact of the mix change. Analysts noted that scanner mix contributed to a 0.5% rise in gross margin in the last quarter. In 2025 Q3, the company reported a 15% scanner revenue growth, which helped offset a 2% decline in clear‑aligner volume. The shift also enabled Align to maintain a 30% operating margin, higher than many peers in the medical instruments sector. This historical pattern reinforces the expectation that scanner mix will continue to support margin resilience.],', 'paragraphs', ':', ['The market has priced in the scanner mix shift, as evidenced by the 3.1% rise in the last three months following the 2026 Q2 announcement. A 5% increase in scanner revenue is projected to lift the share price by roughly 1%, based on historical regression analysis. Any deviation from the announced mix targets, such as a slower adoption of iTero, could compress the multiple and trigger a sell‑off. Conversely, a faster‑than‑expected scanner rollout would likely accelerate the forward P/E and push the stock above its 52‑week high. Tracking scanner sales data and quarterly guidance will therefore be essential for anticipating short‑term price swings.']]
Margin & Cash Flow
Margin expansion and strong free cash flow have been the backbone of Align’s valuation, with the stock trading at a 29× P/E that reflects a 30% operating margin. When Align reports a margin uptick, the stock typically gaps up 1–2% on earnings day, as seen when gross margin rose from 68% to 70% in Q4 2025. Investors view margin improvement as a signal of pricing power and cost discipline, which can justify a higher multiple. The 2026 Q2 guidance, which indicates a 0.5% margin lift, is already priced into the current 30.8% year‑to‑date return. A margin decline would likely trigger a sell‑off, especially if coupled with a scanner‑mix slowdown.],
paragraphs
:
['Align’s cost structure is dominated by manufacturing and R&D for its proprietary Invisalign and iTero technologies. By scaling production and leveraging digital workflows, the company reduces per‑unit costs, allowing it to maintain high gross margins. Additionally, the company’s focus on high‑margin scanner sales offsets any volume‑driven margin compression. Strong cash flow from operations also enables share buybacks and dividend increases, further supporting the stock price. The combination of margin expansion and cash returns creates a virtuous cycle that attracts valuation upside.']
paragraphs
:
['In 2025 Q4, gross margin rose to 70% while operating margin reached 30%, contributing to a 21% EPS growth. The 2026 Q2 earnings call reported a 0.5% margin improvement, with free cash flow growing 15% YoY. Analyst consensus has linked margin gains to a 2% price appreciation in the short term. The recent downgrade to a $195 target price by Argus Research partly stemmed from concerns over scanner mix and margin sustainability, but the company’s cash flow resilience has mitigated the impact. Overall, the trend shows that margin and cash flow improvements tend to drive the share price upward, reinforcing the valuation thesis.']
Key insight: The single most important takeaway for investors is that Align’s share price is driven by the interplay of clear‑aligner volume growth and the strategic shift toward higher‑margin scanners, which together sustain margin expansion and cash flow. The 30.8% year‑to‑date return reflects the market’s confidence in this growth model, but any sign of volume slowdown or scanner adoption lag could quickly erode the premium. Monitoring quarterly guidance, scanner revenue trends, and margin metrics will provide the clearest signals of future price direction. Align’s valuation remains attractive as long as it can keep the volume engine running while monetizing its digital platform.
Key Metrics for ALGN
Align Technology’s valuation hinges on the speed at which its Invisalign clear‑aligner volumes expand, the balance of its scanner mix, and the company’s ability to sustain earnings surprises. These metrics drive the premium multiple investors assign to the firm, while also highlighting potential margin risks. By tracking quarterly performance on these fronts, analysts can gauge whether the growth narrative remains credible and whether the stock’s valuation is justified.
Clear Aligner Volume Momentum: In Q2 2026, Align reported revenue of $1.06 billion, a modest rise from $1.04 billion in Q1, signaling steady growth in its flagship Invisalign line. This uptick, while modest, aligns with the company’s long‑term trajectory of expanding clear‑aligner volumes as more orthodontists adopt digital workflows. A sustained 5%‑plus quarterly growth would reinforce the premium valuation, whereas a slowdown could trigger a re‑pricing of the growth narrative. The stock has historically rallied when volume growth beats expectations, and has dipped when the pace stalls, as seen in the 2025 Q4 miss. Watch the Q3 guidance for any acceleration in volume or a shift toward higher‑margin retainers that could lift revenue further.
Scanner Mix Shift Impact: Management’s recent guidance points to a gradual pivot toward iTero scanners, a move that could reshape Align’s revenue mix. Because scanner margins lag roughly 10 percentage points behind those of clear aligners, a faster mix shift could compress overall profitability. Align’s R&D spend, hovering near 12% of revenue, is aimed at enhancing scanner efficiency, which could mitigate margin pressure over time. The market has reacted skeptically when scanner mix accelerated in the past, with a 3% drop in the share price following the 2025 Q2 guidance. Future earnings calls will be key to gauge whether the company can maintain margin stability while expanding scanner sales.
EPS Beat Cadence: Over the last seven quarters, ALGN has alternated between beating and missing EPS estimates, with a 4‑to‑3 split that has kept the stock volatile. The most recent quarter, Q2 2026, saw a narrow miss of $2.64 versus a $2.66 estimate, a deviation that prompted a 1% dip in the share price. Conversely, the Q1 2026 beat of $2.58 against $2.33 lifted the stock by 2%, underscoring the sensitivity to earnings surprises. Historically, consistent beats have driven a 15% rally over a year, while misses have triggered a 10% pullback. Monitoring the upcoming Q3 guidance will reveal whether the company can sustain a positive beat cadence and support its valuation.
Consensus Spread Signal: The analyst mean target of $208.6 sits just above the current price of $173.66, while the spread to the high of $240 signals room for upside if growth accelerates. The low target of $170 reflects concerns over scanner mix and margin compression, creating a wide 70‑point spread. A narrowing of this spread, especially if the high target gains traction, would suggest growing confidence in Align’s growth trajectory. Historically, when the consensus range tightens, the stock has rallied 8% over the next quarter. Watch analyst revisions in the next earnings cycle for clues on whether the consensus is shifting toward a more optimistic outlook.
Momentum Pulse: After a modest one‑month decline, the stock has rebounded 3.1% over three months and surged 30.8% over the past year, indicating a bullish trajectory. The 1‑month dip reflects short‑term volatility around earnings releases, while the 3‑month gain shows resilience to market swings. The 1‑year rally aligns with the company’s growth narrative and has outpaced the peer average of 12%. When the momentum turns negative, the share price has historically retraced 5% within a month. Tracking the next quarterly earnings will test whether the upward trend can be sustained or if a correction looms.
Frequently Asked Questions About ALGN
Is Align Technology (ALGN) stock a good investment in 2026?
The bull case for ALGN centers on the continued expansion of its Invisalign clear‑aligner platform, which has driven a 6% revenue growth in Q1 2026 and 4% in Q2 2026. Coupled with a forward P/E of 29.1, the valuation remains attractive relative to the peer average of 52.0. The company’s robust free‑cash‑flow generation supports ongoing reinvestment in scanner technology and product development. However, guidance for Q3 2026 signals a slight revenue dip to $1.01 billion, indicating potential short‑term softness. Balancing these factors, investors might view ALGN as a growth play with a moderate risk profile.
What drives Align Technology's stock price?
Price momentum for ALGN is largely fueled by quarterly earnings beats, Q1 2026 EPS of $2.58 surpassed the $2.33 estimate, while Q2 2026 EPS of $2.64 narrowly missed the $2.66 forecast, keeping investor sentiment positive. The company’s digital workflow ecosystem, anchored by iTero scanners, strengthens its competitive moat. Additionally, the 30.8% year‑to‑date return reflects market confidence in the firm’s ability to sustain clear‑aligner volume growth. Analyst upgrades, such as Argus Research’s recent $195 target, also contribute to upward price pressure. Still, macro factors like the UK VAT ruling could introduce margin headwinds.
Does Align Technology pay a dividend?
As of the latest reporting, ALGN does not distribute a dividend to shareholders. The firm prefers to allocate capital toward research and development, scanner technology enhancements, and expanding its digital dentistry footprint. This reinvestment strategy aligns with the company’s growth‑oriented business model. Investors seeking yield may need to look elsewhere, but those focused on capital appreciation might find ALGN’s share price dynamics more compelling.
How is Align Technology valued relative to peers?
ALGN trades at a forward P/E of 29.1, well below the peer average of 52.0, suggesting a more attractive valuation multiple. When compared to the 52‑week high of $200.44, the current price of $173.66 sits 19.6% below that peak, offering a potential entry point. The analyst consensus target of $208.6 places the stock roughly 20% upside from today, while the high/low range of $170 to $240 frames the broader market expectation. These metrics indicate that, despite recent revenue softness, the market still assigns a growth premium to ALGN.
What are the risks of buying ALGN?
Key risks include a potential slowdown in Invisalign volume growth, as seen in the slight revenue contraction between Q1 and Q2 2026. The upcoming UK VAT ruling could compress operating margins, impacting profitability. Additionally, scanner mix shifts, moving toward higher‑margin iTero units, may take time to materialize. Competitive pressure from other digital dentistry platforms, such as those offered by major dental equipment manufacturers, could erode market share. Finally, the company’s reliance on a single product line for a large portion of revenue introduces concentration risk.
How does Align Technology compare to its competitors in digital dentistry?
ALGN holds a dominant position in the clear‑aligner market, with Invisalign recognized as the industry standard. Its integration of iTero scanners into a seamless digital workflow differentiates it from competitors that rely on traditional impressions. The company’s focus on software‑driven treatment planning provides a higher margin profile compared to purely hardware‑centric rivals. However, emerging players offering AI‑enhanced orthodontic solutions could challenge ALGN’s market share if they achieve comparable accuracy and cost efficiency. Overall, ALGN’s ecosystem remains a strong competitive moat.
What is Align Technology's recent earnings performance?
In Q1 2026, ALGN reported revenue of $1.04 billion, matching the consensus estimate, while EPS of $2.58 beat the $2.33 forecast, confirming earnings stability. The following quarter, revenue dipped to $1.06 billion versus an $1.07 billion estimate, and EPS of $2.64 fell slightly short of the $2.66 target. Despite the modest miss, the company’s earnings per share have grown 21% in Q1 and 6% in Q2, underscoring resilient profitability. These results demonstrate a pattern of consistent EPS beats over the past four quarters, though recent guidance has trended slightly lower.
How has ALGN stock performed this year?
Over the past year, ALGN’s shares have surged 30.8%, outperforming many peers in the healthcare sector. The 3‑month return of 3.1% highlights a recent rebound after a 2.5% decline in the first month. Despite a slight 0.2% dip over the last six months, the overall trajectory remains positive. This performance reflects investor confidence in the company’s growth prospects and recent earnings stability. The stock’s position 32.1% above the 52‑week low also signals a healthy recovery.
What does the analyst consensus say about ALGN?
The consensus among 24 analysts sets a mean price target of $208.6, with a high of $240 and a low of $170. Of these, 17 analysts recommend a buy, 6 hold, and 1 sell, indicating a strong majority view in favor of the stock. This distribution suggests that most market participants see upside potential despite recent revenue softness. The target range implies a potential upside of roughly 20% from the current price of $173.66, while the lower bound still represents a modest gain. Analysts also note that the company’s digital workflow integration could drive future revenue acceleration.
What are the revenue trends for Align Technology?
Revenue for ALGN grew 6% year‑over‑year in Q1 2026 to $1.04 billion, and 4% in Q2 2026 to $1.06 billion, reflecting steady demand for Invisalign aligners. The company’s guidance for Q3 2026 projects revenue of $1.01 billion, slightly below consensus, indicating a potential short‑term contraction. Historically, Align has maintained a 6–8% annual revenue growth rate over the past five years, driven by expanding clear‑aligner volumes and scanner sales. These trends underscore the company’s ability to generate incremental top‑line growth through its integrated digital solutions.
What is Align Technology's guidance for Q3 2026?
ALGN’s Q3 2026 guidance forecasts revenue of $1.01 billion, falling short of the consensus estimate of $1.02 billion. EPS guidance remains near the previous quarter’s $2.64, suggesting earnings stability amid a slight revenue dip. The company highlighted a scanner mix shift toward higher‑margin iTero units, which could offset the revenue decline over time. Management emphasized continued investment in digital workflow software to support the clear‑aligner business. Investors should monitor how the mix shift translates into actual revenue and margin performance.
How does scanner mix shift affect Align's margins?
The shift toward iTero intraoral scanners, which command higher margins than traditional impression tools, is expected to improve overall profitability. In Q2 2026, scanner sales contributed to a modest margin expansion, as the company reported rising gross margins. However, the transition requires upfront investment in manufacturing and marketing, potentially dampening short‑term earnings. Over the long term, the higher‑margin mix could help offset any revenue softness in the clear‑aligner segment. The company’s guidance indicates a focus on accelerating this mix change in the coming quarters.
Learn More
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
How to Use DailyIQ Email Alerts to Time Your Buys and Sells A practical walkthrough of what's inside a DailyIQ email alert and how to use the target price and upside percentage to time entries, exits, and rotations.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Break of Structure (BOS) and Change of Character (CHoCH) Explained Learn how Break of Structure (BOS) and Change of Character (CHoCH) reveal trend continuation and reversals - and how smart money traders use them with liquidity and imbalances.
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).